Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator
Christopher G. Thomson(University of Hertfordshire), Savithri Ramurthy(FuelCell Energy (United States)), Diheng Luo, Feven Tameire(FuelCell Energy (United States)), Mark J. Mulvihill(FuelCell Energy (United States)), Eric P. A. Talbot(University of Hertfordshire), Paulina M. Wojnarowicz(Memorial Sloan Kettering Cancer Center), Benjamin F. Rahemtulla(University of Hertfordshire), Bradley Sherborne(University of Hertfordshire), Fenfen Xiao, Alan C. Rigby(FuelCell Energy (United States)), Thomas D. Aicher(Lycera (United States)), David Surguladze(Intellicell Biosciences (United States)), S. Taylor(Pharmaron (United Kingdom)), Yi Wang(Chinese Academy of Sciences), Hongwen Du, Baozhong Li, An‐Hu Li(FuelCell Energy (United States)), Weiwei Cheng, Sanjeev Sood(University of Hertfordshire), Eric S. Lightcap, Pengwei Pan, Crissy Dudgeon(Rutgers, The State University of New Jersey)
Cited by 16
Related Papers
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae
|Cell Metabolism|2019|521
Wip1 Phosphatase Modulates ATM-Dependent Signaling Pathways
|Molecular Cell|2006|347
Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing
|Genes & Development|2015|278
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
|Nature Chemical Biology|2017|228